만성 B형간염 환자에서 hepatitis B core antigen 의 발현과 분포 위치에 따른 라마부딘의 치료반응
Hepatitis B core antigen expression pattern predicts response to lamivudine therapy in patients with chronic hepatitis B
2
조회
0
다운로드
2
인용
0
참고문헌
초록
Backgrounds/Aims: Negative hepatitis B core antigen (HBcAg) staining in hepatocytes is indicative of viral replication by an active immune response. HBcAg is expressed mainly in the cytoplasm in patients with active hepatitis and hepatocyte regeneration, and mainly in the nuclei of hepatocytes in patients with minimal liver injury in the absence of hepatocyte regeneration. The aim of this study was to elucidate whether the existence and expression pattern of HBcAg predicts the response to antiviral treatment. Methods: The study involved 58 patients with biopsy-proven chronic hepatitis B who were treated with lamivudine. Hepatitis B e antigen (HBeAg), antibody to HBeAg, hepatitis B virus DNA, and alanine aminotransferase in serum were recorded every 3 months. The inflammation grade and the fibrosis stage of chronic hepatitis were scored from 0 to 4 according to lobular inflammation, portal inflammation, periportal inflammation, and fibrosis. Results: The 58 patients included 49(84%) HBcAg-positive patients, with HBcAg staining confined to the cytoplasm in 15(31%) and in both cytoplasm and nuclei in 34(69%). The grade of lobular inflammation and the total histology score were significantly higher in patients with cytoplasmic expression of HBcAg than in HBcAg- negative patients (lobular inflammation: 2.9 vs 2.1, P=0.02; total histology score: 12.2 vs 10.3, P=0.04). The virologic responses at 3, 6, 9, and 12 months differed significantly between the cytoplasmic and mixed expression groups (P<0.01). Conclusions: The expression pattern of HBcAg (including its possible absence) before initial therapy appears to predict the response to antiviral treatment.
Abstract
Backgrounds/Aims: Negative hepatitis B core antigen (HBcAg) staining in hepatocytes is indicative of viral replication by an active immune response. HBcAg is expressed mainly in the cytoplasm in patients with active hepatitis and hepatocyte regeneration, and mainly in the nuclei of hepatocytes in patients with minimal liver injury in the absence of hepatocyte regeneration. The aim of this study was to elucidate whether the existence and expression pattern of HBcAg predicts the response to antiviral treatment. Methods: The study involved 58 patients with biopsy-proven chronic hepatitis B who were treated with lamivudine. Hepatitis B e antigen (HBeAg), antibody to HBeAg, hepatitis B virus DNA, and alanine aminotransferase in serum were recorded every 3 months. The inflammation grade and the fibrosis stage of chronic hepatitis were scored from 0 to 4 according to lobular inflammation, portal inflammation, periportal inflammation, and fibrosis. Results: The 58 patients included 49(84%) HBcAg-positive patients, with HBcAg staining confined to the cytoplasm in 15(31%) and in both cytoplasm and nuclei in 34(69%). The grade of lobular inflammation and the total histology score were significantly higher in patients with cytoplasmic expression of HBcAg than in HBcAg- negative patients (lobular inflammation: 2.9 vs 2.1, P=0.02; total histology score: 12.2 vs 10.3, P=0.04). The virologic responses at 3, 6, 9, and 12 months differed significantly between the cytoplasmic and mixed expression groups (P<0.01). Conclusions: The expression pattern of HBcAg (including its possible absence) before initial therapy appears to predict the response to antiviral treatment.
참고문헌 (26)
- Ganem D, "Hepatitis B virus infection — natural history and clinical consequences", N Engl J Med, 350, pp.1118~1129 (2004)
- Huang CF, "The immune response induced by hepatitis B virus principal antigens", Cell Mol Immunol, 3, pp.97~106 (2006)
- Hsu HC, "Biologic and prognostic significance of hepatocyte hepatitis B core antigen expressions in the natural course of chronic hepatitis B virus infection", J Hepatol, 5, pp.45~50 (1987)
- Naoumov NV, "Detection of hepatitis B virus antigens in liver tissue. A relation to viral replication and histology in chronic hepatitis B infection", Gastroenterology, 99, pp.1248~1253 (1990)
- Chu CM, "Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic", membranous hepatitis B core antigen as a possible target for immune hepatocytolysis, 1987, pp.92, 220~225
- Kim TH, "The degrees of hepatocyte cytoplasmic expression of hepatitis B core antigen correlate with histologic activity of liver disease in the young patients with chronic hepatitis B infection", J Korean Med Sci, 21, pp.279~283 (2006)
- Kim CW, "Correlation of hepatitis B core antigen and beta-catenin expression on hepatocytes in chronic hepatitis B virus infection: relevance to the severity of liver damage and viral replication", J Gastroenterol Hepatol, 22, pp.1534~1542
- Choi JY, "The efficacy of lamivudine in Korean patients with chronic hepatitis B", Korean J Hepatol 2005;11:25-30, 11, pp.25~30 (2005)
- Mizukoshi E, "Cellular immune responses to the hepatitis B virus polymerase", J Immunol, 173, pp.5863~5871 (2004)
- Boni C, "Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy", Hepatology, 33, pp.963~971 (2001)
- Boni C, "Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B", J Hepatol, 39, pp.595~605 (2003)
- Cho JH, "Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients", Korean J Hepatol, 14, pp.58~66 (2008)
- Park CI, "New classification of chronic hepatitis: introduction and application", J. Korean Med Assoc, 41, pp.323~329 (1998)
- Ferrari C, "Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen", J Clin Invest, 88, pp.214~222 (1991)
- Penna A, "Long-lasting memory T cell responses following self-limited acute hepatitis B", J Clin Invest, 98, pp.1185~1194 (1996)
- Thimme R, "CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection", J Virol, 77, pp.68~76 (2003)
- Maini MK, "The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection", J Exp Med, 191, pp.1269~1280 (2000)
- Webster GJ, "Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy", J Virol, 78, pp.5707~5719 (2004)
- Ning B, "Nucleolar localization of human hepatitis B virus capsid protein", J Virol, 78, pp.13653~13668 (2004)
- Akiba T, "Relationship between the replication of hepatitis B virus and the localization of virus nucleocapsid antigen (HBcAg) in hepatocytes", J Gen Virol, 68, pp.871~877 (1987)
- Chu CM, "The degrees of hepatocyte nuclear but not cytoplasmic expression of hepatitis B core antigen reflect the level of viral replication in chronic hepatitis B virus infection", J Clin Microbiol, 35, pp.102~105 (1997)
- Chu CM, "Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels", Am J Med, 116, pp.829~834 (2004)
- Chang JJ, "Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy", J Virol, 79, pp.3038~3051 (2005)
- Tang TJ, "Intrahepatic CD8 T- lymphocytes and HBV core expression in relation to response to antiviral therapy for chronic hepatitis B patients", J Med Virol, 72, pp.215~222 (2004)
- "Korean J Hepatol 2006;12(Supple 3)", S83~
- Uzun Y, "Hepatitis B core antigen expression pattern reflects the response to anti-viral treatment", J Gastroenterol Hepatol, 21, pp.977~981 (2006)